SCHEMBL7226796

SCHEMBL7226796

CC(=O)N1CCC(CCCC(=O)Cl)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.40
EPHX1 P07099 2/20 0.40
ITGB3 P05106 2/20 0.40
ITGA2B P08514 2/20 0.40
GNAI3 P08754 2/20 0.40
GNAO1 P09471 2/20 0.40
GNAI1 P63096 2/20 0.40
HDAC3 O15379 4/20 0.40
HDAC4 P56524 4/20 0.40
HDAC1 Q13547 4/20 0.40
HDAC7 Q8WUI4 4/20 0.40
HDAC2 Q92769 4/20 0.40
HDAC10 Q969S8 4/20 0.40
HDAC11 Q96DB2 4/20 0.40
HDAC8 Q9BY41 4/20 0.40
HDAC6 Q9UBN7 4/20 0.40
HDAC9 Q9UKV0 4/20 0.40
HDAC5 Q9UQL6 4/20 0.40
FAAH O00519 2/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505234 0.89 EPHX2 (0.42) EPHX2EPHX1GNAI3GNAO1GNAI1
Hydrochloric Acid SCHEMBL5981760 0.86 EPHX2 (0.40) EPHX2EPHX1GNAI3GNAO1GNAI1
SCHEMBL7227535 0.84 ITGB3 (0.55) EPHX2EPHX1ITGB3ITGA2BGNAI3
SCHEMBL5013505 0.84 ITGB3 (0.41) EPHX2EPHX1ITGB3ITGA2BGNAI3
SCHEMBL7299175 0.80 AKR1C3 (0.45) EPHX2EPHX1ITGB3ITGA2BGNAI3
SCHEMBL12561511 0.80 POLB (0.51) EPHX2EPHX1ITGB3ITGA2BGNAI3
SCHEMBL14086616 0.80 HDAC3 (0.60) EPHX2EPHX1ITGB3ITGA2BHDAC3
SCHEMBL14086615 0.80 TSHR (0.44) EPHX2EPHX1ITGB3ITGA2BGNAI3
SCHEMBL3478015 0.80 FAAH (0.57) EPHX1FAAH
SCHEMBL23710149 0.79 SIGMAR1 (0.44) EPHX2EPHX1ITGB3ITGA2BGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
EP-0602242-A1 BENZISOXAZOLE COMPOUND AND USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-06-22 EP disclosed